Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Zhengzhou 450046, China.
College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China.
J Tradit Chin Med. 2019 Aug;39(4):550-558.
To observe toxicity-reduced effects of Leigongteng (Radix et Rhizoma Tripterygii) (LGT) via compatibility with Jinqiancao (Herba Lysimachiae) (JQC) in H22-bearing mice and investigate the possible underlying mechanism, and further explore whether JQC can enhance LGT-evoked anti-tumor effect.
H22-bearing mice were orally administered with LGT alone and its compatibility with JQC, and tumors, serum, livers and kidneys were collected to evaluate the toxicity-reduced efficacy and the possible mechanism.
LGT evoked significantly elevated biochemical indicators including serum alanine / aspartate transaminase (ALT/AST), creatinine (Cr) and urea nitrogen (BUN) as well as pathological damage in mice, which were all obviously reversed by JQC via compatibility at the ratios from 4/1 to 1/4. Further analysis indicated that pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), and malondialdehyde (MDA) levels significantly decreased, while anti-inflammatory cytokine interleukin (IL)-10, and glutathione (GSH), GSH-s transferase (GST), GSH peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) levels all increased in livers and kidneys of mice. Besides, after compatibility with JQC at the ratios of 4/1, 2/1, 1/1, 1/2 and 1/4, LGT-decreased tumor weight was further decreased by 48.4%, 57.3%, 54.0%, 49.3% and 52.9%, respectively (all P < 0.01).
JQC could reduce LGT-induced hepatotoxicity and nephrotoxicity, and enhance the antitumor efficacy via compatibility with JQC, and the toxicity-reduced mechanism could involve inhibiting hepatic and kidney oxidative stress and inflammation.
观察雷公藤（藤根和藤茎）（LGT）与金钱草（Herba Lysimachiae）（JQC）配伍对 H22 荷瘤小鼠的减毒作用，并探讨其可能的作用机制，进一步探讨 JQC 是否能增强 LGT 诱发的抗肿瘤作用。
用 LGT 单独及其与 JQC 的配伍给 H22 荷瘤小鼠灌胃，收集肿瘤、血清、肝脏和肾脏，评估减毒效果和可能的机制。
LGT 引起的血清丙氨酸/天冬氨酸转氨酶（ALT/AST）、肌酐（Cr）和尿素氮（BUN）等生化指标明显升高，以及小鼠的病理损伤，均被 JQC 以 4/1 至 1/4 的比例通过配伍明显逆转。进一步分析表明，炎性细胞因子肿瘤坏死因子-α（TNF-α）和丙二醛（MDA）水平显著降低，而抗炎细胞因子白细胞介素（IL）-10、谷胱甘肽（GSH）、谷胱甘肽-s 转移酶（GST）、谷胱甘肽过氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）和过氧化氢酶（CAT）水平在肝脏和肾脏中均增加。此外，与 JQC 以 4/1、2/1、1/1、1/2 和 1/4 的比例配伍后，LGT 降低的肿瘤重量分别进一步降低了 48.4%、57.3%、54.0%、49.3%和 52.9%（均 P<0.01）。
JQC 可通过与 JQC 配伍减轻 LGT 引起的肝毒性和肾毒性，并增强抗肿瘤疗效，其减毒机制可能涉及抑制肝、肾氧化应激和炎症。
